Enanta Pharmaceuticals (ENTA)
(Delayed Data from NSDQ)
$12.58 USD
-0.91 (-6.75%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $12.55 -0.03 (-0.24%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Enanta Pharmaceuticals (ENTA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$16.83 | $27.00 | $10.00 | 24.76% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Enanta Pharmaceuticals comes to $16.83. The forecasts range from a low of $10.00 to a high of $27.00. The average price target represents an increase of 24.76% from the last closing price of $13.49.
Analyst Price Targets (6 )
Broker Rating
Enanta Pharmaceuticals currently has an average brokerage recommendation (ABR) of 2.14 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 2.67 a month ago based on six recommendations.
Of the seven recommendations deriving the current ABR, four are Strong Buy, representing 57.14% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ENTA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 2 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 3 | 3 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.14 | 2.67 | 2.67 | 2.71 | 2.71 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/7/2024 | Not Identified | Not Identified | Hold | Strong Buy |
8/6/2024 | Evercore Partners | Liisa A Bayko | Not Available | Strong Buy |
8/6/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
5/7/2024 | JMP Securities | Roy Buchanan | Strong Buy | Strong Buy |
5/6/2024 | SVB Securities | Roanna Ruiz | Hold | Hold |
2/7/2024 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.14 |
ABR (Last week) | 2.67 |
# of Recs in ABR | 7 |
Average Target Price | $16.83 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 253 |
Current Quarter EPS Est: | -1.22 |